Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
โ Scribed by F. Peintinger; H. M. Kuerer; S. E. McGuire; R. Bassett; L. Pusztai; W. F. Symmans
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 289 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.6044
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Background
Neoadjuvant chemotherapy for breast cancer reduces tumour cellularity, the percentage of the primary tumour area that is composed of invasive tumour cells. Minimal residual tumour cellularity (5 per cent or less of tumour area composed of invasive tumour cells) may be associated with an increased risk of false-negative intraoperative margins. The aim of this study was to evaluate the incidence of minimal residual tumour cellularity after neoadjuvant chemotherapy and its impact on the frequency of false-negative margins and conversion from breast-conserving surgery to mastectomy.
Methods
The final pathology slides of 510 patients who had surgery after neoadjuvant chemotherapy were reviewed.
Results
Of 396 patients with residual invasive breast cancer after neoadjuvant chemotherapy, 100 specimens (25ยท3 per cent) had minimal residual cellularity; this was more frequent in patients with invasive lobular carcinoma (17ยท0 versus 5ยท1 per cent; P < 0ยท001) or well and moderately differentiated carcinoma (68ยท0 versus 52ยท4 per cent; P = 0ยท007). Among 149 patients who had initial breast-conserving surgery, false-negative intraoperative margin rates were 23 per cent in specimens with minimal and 13ยท8 per cent in those with higher residual cellularity (P = 0ยท210). There was no significant difference in the rate of conversion to mastectomy between the groups.
Conclusion
Minimal residual cellularity after neoadjuvant chemotherapy occurred in about 25 per cent of specimens, but did not alter the rate of false-negative intraoperative margins.
๐ SIMILAR VOLUMES
Patients with metastatic non-seminomatous testicular cancer can be cured by cisplatin-based chemotherapy. After chemotherapy, surgical resection is a generally accepted treatment to remove remnants of the initial metastases since residual tumor may still be present (mature teratoma or viable cancer
## Abstract ## Background An important benefit of neoadjuvant chemotherapy is the increased potential for breast-conserving surgery. At present the response of axillary lymph node metastases to chemotherapy is not easily assessed, rendering axilla-conserving treatment difficult. The aim was to ass
We have investigated the relationship between immunohistochemically determined p53 status and outcome in 277 women with node-positive primary breast cancer who, following tumour excision and axillary clearance, were randomised to receive either 6 cycles of cyclophosphamide/methotrexate/S-fluorouraci
## BACKGROUND. After chemotherapy for metastatic, nonseminomatous testicular cancer, small, retroperitoneal lymph nodes still harbor mature teratoma or viable cancer cells in less than half of patients with normal tumor markers. Surgical resection is an effective treatment to remove residual masse
Background and Objectives: Removal of the entire tumor by breastconserving surgery is important, but the determinants of adequate excision have not been established. Methods: A prospective study of 55 consecutive lumpectomies for early breast cancer was performed to study the correlation between tou